7,343 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 7,343 shares of the company’s stock, valued at approximately $842,000.

A number of other institutional investors and hedge funds have also bought and sold shares of KYMR. GAMMA Investing LLC grew its position in shares of Kymera Therapeutics by 27.5% during the 2nd quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock worth $52,000 after buying an additional 98 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in shares of Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after buying an additional 424 shares during the period. Larson Financial Group LLC increased its stake in shares of Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after buying an additional 349 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of Kymera Therapeutics in the fourth quarter valued at about $63,000. Finally, Osaic Holdings Inc. raised its holdings in shares of Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after acquiring an additional 1,083 shares in the last quarter.

Kymera Therapeutics Trading Down 0.0%

NASDAQ:KYMR opened at $121.38 on Wednesday. Kymera Therapeutics, Inc. has a twelve month low of $39.84 and a twelve month high of $130.05. The company has a market cap of $10.09 billion, a PE ratio of -37.46 and a beta of 1.95. The company’s 50 day moving average is $107.00 and its two-hundred day moving average is $91.12.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The business had revenue of $65.00 million during the quarter, compared to analysts’ expectations of $32.78 million. During the same quarter last year, the company posted ($0.95) earnings per share. The business’s quarterly revenue was up 465.2% on a year-over-year basis. As a group, analysts expect that Kymera Therapeutics, Inc. will post -3.78 EPS for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In related news, Director Bruce Booth sold 467,878 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $110.29, for a total value of $51,602,264.62. Following the completion of the transaction, the director owned 472,267 shares in the company, valued at $52,086,327.43. This trade represents a 49.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Bruce N. Jacobs sold 77,109 shares of the firm’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total value of $8,864,450.64. Following the completion of the transaction, the chief financial officer owned 244,883 shares of the company’s stock, valued at $28,151,749.68. This trade represents a 23.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 3,604,813 shares of company stock valued at $387,557,004 in the last quarter. Insiders own 15.98% of the company’s stock.

Analyst Ratings Changes

KYMR has been the topic of several recent research reports. Truist Financial increased their target price on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the stock a “buy” rating in a report on Monday, June 29th. BTIG Research restated a “buy” rating and issued a $134.00 price target on shares of Kymera Therapeutics in a report on Thursday, June 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Friday, July 17th. Deutsche Bank Aktiengesellschaft began coverage on shares of Kymera Therapeutics in a research note on Thursday, July 30th. They set a “hold” rating and a $120.00 price objective on the stock. Finally, Barclays lifted their price objective on shares of Kymera Therapeutics from $133.00 to $139.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Twenty equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Kymera Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $125.65.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.